BioCentury | Jan 7, 2013

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
BioCentury | Dec 24, 2012
Clinical News

DPP Syphilis Screen & Confirm diagnostic data

...Chinese sexually transmitted disease (STD) clinics and high-risk groups in outreach settings showed that Chembio's DPP Syphilis Screen &... syphilis in whole blood samples (n=1,323) vs. Treponema pallidum particle agglutination (TPPA). Additionally, the DPP Syphilis Screen &...
...and 94.6% sensitivity and 99.6% specificity in blood plasma samples (n=1,323) vs. TPPA. Furthermore, the DPP Syphilis Screen &...
BioCentury | Oct 17, 2011
Clinical News

DPP Syphilis Screen & Confirm regulatory update

...Chembio received CE Mark approval for its DPP Syphilis Screen & Confirm assay to diagnose syphilis. The company plans...
...and treponemal antibodies to syphilis in whole blood. Chembio Diagnostics Inc. (OTCBB:CEMI), Medford, N.Y. Product: DPP Syphilis Screen &...
BioCentury | Jan 10, 2011

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
Items per page:
1 - 4 of 4